Y-mAbs Therapeutics Investors Get Final OK For $19.7M Deal

By Sydney Price · October 29, 2024, 10:18 PM EDT

A New York federal judge has granted final approval to a $19.7 million settlement between Y-mAbs Therapeutics and investors who claim the company misrepresented the likelihood that the U.S. Food and...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Case Information

Case Title

Corwin v. Y-mAbs Therapeutics, Inc. et al

Case Number

Court

New York Southern

Nature of Suit

Securities/Commodities

Date Filed

January 18, 2023

Recent Articles By Sydney

November 15, 2024
Healthcare Co. PACS Made False Claims Before IPO, Suit Says
November 13, 2024
Biotech Brass Misled Investors About Cancer Drugs, Suit Says
October 29, 2024
Biopharma Co. Escapes Investor Suit Over Drug Approval Lies
October 17, 2024
Acadia Hid Wrongful Detainment Of Patients, Investor Claims
September 25, 2024
Feds Urge Judge Not To Ax Novel Insider Trading Conviction
September 24, 2024
Philips Must Face Investor Suit Over FDA Compliance Issues
July 18, 2024
Ocugen Execs Hit With Derivative Suit Over Shoddy Controls
July 15, 2024
Walgreens Investor Sues Over Challenged Pharmacy Division
July 10, 2024
Skin Care Tech Co. Says Suit Shows 'Rough' Year, Not Fraud
July 08, 2024
UnitedHealth Brass Face Investor Suit Over Merger Probe